Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

NCT06100874 is registered in ClinicalTrials.gov with Adrienne G. Waks as lead sponsor.

NCT NCT06100874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06100874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Lead sponsor
Adrienne G. Waks
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 20, 2023
Completion date
November 30, 2027
Enrollment
28 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female, breast cancer metastatic, her 2 positive breast cancer